Edit
Turning Point Therapeutics, Inc
https://tptherapeutics.com/Last activity: 13.06.2022
Probably Closed
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Location: United States, California, San Diego
Employees: 201-500
Total raised: $327.5M
Founded date: 2013
Investors 7
| Date | Name | Website |
| - | SV Tech Ve... | svtechvent... |
| - | Foresite C... | foresiteca... |
| - | ChinaRock ... | crcmventur... |
| - | Harbinger ... | harbingerv... |
| - | OrbiMed | orbimed.co... |
| - | HBM Partne... | hbmpartner... |
| - | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.09.2019 | - | $202.5M | - |
| 24.10.2018 | - | $80M | Foresite C... |
| 23.05.2017 | Series C | $45M | OrbiMed |
Mentions in press and media 17
| Date | Title | Description |
| 13.06.2022 | Bristol Myers Squibb Buys Turning Point | Bristol Myers Squibb (BMS) is further strengthening its ties to San Diego. On June 3, the New York-based global biopharmaceutical company announced it had acquired Turning Point Therapeutics, Inc., a clinical-stage precision oncology compan... |
| 07.06.2022 | How air taxi unicorn Volocopter plans to fund its 2024 service debut | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. The year is 2024, and you have just deplaned your flight in Rome. It seems like a great time to c... |
| 06.06.2022 | Why the fates of PE and VC-backed companies may diverge in 2022 | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. We’ve been hearing it for a few months now: There are rough times ahead for private companies. Pa... |
| 13.04.2022 | Turning Point looks to challenge Pfizer, Roche with new early data for lead lung cancer drug | Turning Point Therapeutics shared a Phase I/II update for its lead drug candidate repotrectinib, but investors said they were expecting slightly better. In 71 total TKI-naive patients, the confirmed objective response ra... |
| 11.11.2021 | Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics | SAN DIEGO and BENGALURU, India, Nov. 11, 2021 /PRNewswire/ -- Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry and in-vitro ADME Service offerings. Jubilant Biosys provides services ... |
| 11.09.2019 | Turning Point Therapeutics Raises $202.5M in Follow-On Offering | After raising $175.2 million in an initial public offering this spring, Turning Point Therapeutics has returned to the public market. The cancer drug developer on Sept. 10 raised $202.5 million in a follow-on offering. Turning Point sold 4.... |
| 14.04.2019 | Turning Point Therapeutics Lays Out Terms for $125M IPO | Turning Point Therapeutics — which is developing drugs for treatment-resistant cancers — set terms for an initial public offering. The company plans to sell 7.35 million shares at $16 to $18 each, which at the midpoint of the range would ge... |
| 19.10.2018 | TP Therapeutics Completes $80M Mezzanine Financing | TP Therapeutics, a San Diego, CA-based clinical-stage precision oncology company developing novel drugs that address treatment resistance, completed an $80m round of mezzanine financing. The round was led by Foresite Capital and venBio Part... |
| 19.10.2018 | TP Therapeutics raises $80M as CMO Countouriotis takes the helm | TP Therapeutics has netted $80 million and a new CEO as it looks to move its lead candidate targeting drug-resistant tumors, repotrectinib (TPX-0005), into phase 2 research early next year. Sponsored by Agilent Technologies How would you li... |
| 19.10.2018 | TP Therapeutics raises $80M as CMO Countouriotis takes the helm | TP Therapeutics has netted $80 million and a new CEO as it looks to move its lead candidate targeting drug-resistant tumors, repotrectinib (TPX-0005), into phase 2 research early next year. Chief Medical Officer Athena Countouriotis, M.D., ... |
Show more